

References

I-9049

1. Preferred Drug List (PDL) Prior Authorization Criteria. North Dakota Department of Human Services. Medical Services Division. <http://www.hidesigns.com/ndmedicaid/pdl/>
2. Vyjuvek (beremagene geperpavec-svdt) biological suspension mixed with excipient gel for topical application [package insert]. Krystal Biotech, Inc. Pittsburgh, PA. Revised 05/2023.
3. Micromedex DrugDex Compendium®. 2023. Beremagene geperpavec-svdt.
4. Clinical Pharmacology Compendia™. 2023. Tampa FL: Gold Standard, Inc. Beremagene geperpavec-svdt.
5. Beremagene geperpavec-svdt In: AHFS Drug Information Online Electronic Medical Library. Bethesda, MD: American Society of Health-System Pharmacists. Updated February 1, 2021.
6. Gurevich I, Agarwal P, Zhang P, et al. In vivo topical gene therapy for recessive dystrophic epidermolysis bullosa: a phase 1 and 2 trial. *Nature Medicine*. 2022; 28:780-788.
7. Guide SV, Gonzalez ME, Bagci IS, et al. Trial of beremagene geperpavec (BVEC) for dystrophic epidermolysis bullosa. *NEJM*. 2022; 387(24):2211-2219